News

A lipid nanoparticle designed to deliver genetic therapy to lung cells could be used as a platform to treat lung-related diseases like cystic fibrosis (CF), a mouse study found. Researchers developed a way to identify lipid nanoparticles — fatty molecules that help deliver genetic material to cells — that…

The Cystic Fibrosis Foundation (CFF) is encouraging individuals and nonprofits to apply by April 5 for one of its 2024 CFF Impact Grants, which provide as much as $10,000 in funding to programs that help people with cystic fibrosis (CF) or their families live their lives to the…

A persistently stuffy nose is a big concern for people with cystic fibrosis (CF) who have chronic nose inflammation, but loss of smell isn’t as significant a worry, according to a new study that used the SinoNasal Outcome Test (SNOT-22). “Nasal congestion and post-nasal discharge were top priorities reported…

In the years after Kalydeco (ivakaftor) became available, the use of pancreatic enzyme replacement therapy (PERT) fell among people with cystic fibrosis (CF) in the U.S. who were eligible for the therapy. That’s according to “Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis…

Zinc may be key to reducing bacterial infections in people with cystic fibrosis (CF), researchers at the University of Queensland have found. They discovered that defects in the CFTR protein, the underlying cause of CF, interfered with the bacteria-killing function of immune cells known as macrophages. They were able…

The European Commission has granted orphan drug designation to ARCT-032, an inhaled experimental treatment for cystic fibrosis (CF) developed by Arcturus Therapeutics. Orphan drug designation is designed to encourage developing therapies for rare and serious diseases, those affecting not more than 5 in every 10,000 people in the European Union…

A European Medicines Agency (EMA) committee recommends extending the label for Kalydeco (ivacaftor) to children with cystic fibrosis (CF) as young as a month who carry at least one CFTR gating mutation. If the European Commission (EC) accepts the endorsement by the Committee for Medicinal Products for Human…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly reduced rates of colonization with the bacterium Pseudomonas aeruginosa in adults with cystic fibrosis (CF) at a center in Kentucky. Trikafta also reduced the need for mucus-clearing medicines and antibiotics, according to the study “Impact of Elexacaftor/tezacaftor/ivacaftor on Respiratory Colonization…

ReCode Therapeutics has launched a Phase 1 clinical trial to evaluate the safety of RCT2100, its investigational genetic medicine for  cystic fibrosis (CF), in healthy volunteers and the first group of participants has been dosed. RCT2100 is being developed for CF patients with class I mutations in the…

Compounds secreted by Lactobacillus, a group of bacteria commonly used in probiotics, are able to impede the growth of Pseudomonas aeruginosa isolated from the lungs of people with cystic fibrosis (CF). That’s according to the study, “Cell-free supernatants from Lactobacillus strains exert antibacterial, antibiofilm, and antivirulence…